Illumina Inc. ($ILMN) Stock Forecast: Down 8.7% Today

What is Illumina Inc.?

Illumina Inc. (ILMN) Market: Illumina Inc. (ILMN) is a leading biotechnology company specializing in genetic sequencing and array-based technologies, renowned for its innovation in genomics research, clinical diagnostics, and drug development.

Why is Illumina Inc. going down?

ILMN stock is down 8.7% on Aug 1, 2025 17:51

• Despite reporting better-than-expected earnings and revenues for the second quarter, Illumina's stock experienced a significant bearish movement.
• The market's reaction may have been influenced by profit-taking behaviors, potentially following a period of favorable outcomes, leading to a temporary decline in the stock price.
• The results slightly below some investors' expectations could have induced a sense of disappointment, contributing to the bearish sentiment in the market.
• Nevertheless, the observed bearish movement could be a brief response to the earnings report, and the long-term outlook for Illumina appears promising, given its strong position in the biotechnology sector.

ILMN Price Chart

ILMN Technical Analysis

ILMN News

These Analysts Boost Their Forecasts On Illumina Following Upbeat Results - Illumina ( NASDAQ:ILMN )

Illumina, Inc. ILMN reported better-than-expected earnings for the second quarter on Thursday. The company posted quarterly earnings of $1.19 per share which beat the analyst consensus estimate of $1.01 per share. The company reported quarterly sales of $1.059 billion which beat the analyst ...

https://www.benzinga.com/analyst-stock-ratings/price-target/25/08/46800842/these-analysts-boost-their-forecasts-on-illumina-following-upbeat-results

Illumina ( ILMN ) Q2 Earnings and Revenues Surpass Estimates

Illumina (ILMN) delivered earnings and revenue surprises of +16.67% and +1.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2645710/illumina-ilmn-q2-earnings-and-revenues-surpass-estimates

Gear Up for Illumina ( ILMN ) Q2 Earnings: Wall Street Estimates for Key Metrics

Besides Wall Street's top-and-bottom-line estimates for Illumina (ILMN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.

https://www.zacks.com/stock/news/2638328/gear-up-for-illumina-ilmn-q2-earnings-wall-street-estimates-for-key-metrics

Trending Today

Lithia Motors Inc. ($LAD) Stock Forecast: Up 5.1% Today

ONEOK Inc. ($OKE) Stock Forecast: Down 5.0% Today

Transdigm Group Incorporated Inc. ($TDG) Stock Forecast: Down 12.7% Today

Eaton Corporation PLC ($ETN) Stock Forecast: Down 6.7% Today

Palantir Technologies Inc ($PLTR) Stock Forecast: Up 7.2% Today

Pfizer Inc. ($PFE) Stock Forecast: Up 5.0% Today

Astera Labs Inc ($ALAB) Stock Forecast: Down 5.0% Today

Bruker Corporation ($BRKR) Stock Forecast: Down 7.2% Today

Bumble Inc. ($BMBL) Stock Forecast: Down 5.2% Today

MercadoLibre Inc. ($MELI) Stock Forecast: Up 3.3% Today

Illumina Inc. Price History

25.05.2025 - ILMN Stock was up 4.0%

• Today, Illumina experienced strong bullish movement following its acquisition of SomaLogic. This strategic move aims to enhance Illumina's biomarker capabilities and solidify its position in the healthcare sector.
• The acquisition is viewed favorably as it enriches Illumina's product portfolio and diversifies its revenue streams, sparking investor optimism and increasing stock interest.
• Comparative value analysis positions Illumina as a standout among its peers, underlining the market's acknowledgment of its growth potential and future profitability. This recognition further amplifies investor trust and propels the stock price upward.

01.07.2025 - ILMN Stock was down 10.2%

• Despite Illumina (ILMN) surpassing earnings and revenue estimates in Q2, the stock experienced a strong bearish movement.
• The market may have reacted negatively due to profit-taking by investors after a period of strong performance leading up to the earnings release.
• Additionally, there could be concerns about future growth prospects or guidance provided by the company that did not meet heightened market expectations.
• It's possible that some investors were expecting even better results, leading to a sell-off in the stock despite the positive earnings surprise.

01.07.2025 - ILMN Stock was down 8.7%

• Despite reporting better-than-expected earnings and revenues for the second quarter, Illumina's stock experienced a significant bearish movement.
• The market's reaction may have been influenced by profit-taking behaviors, potentially following a period of favorable outcomes, leading to a temporary decline in the stock price.
• The results slightly below some investors' expectations could have induced a sense of disappointment, contributing to the bearish sentiment in the market.
• Nevertheless, the observed bearish movement could be a brief response to the earnings report, and the long-term outlook for Illumina appears promising, given its strong position in the biotechnology sector.

22.06.2025 - ILMN Stock was up 5.5%

• Despite differing views, ILMN saw a strong bullish movement today.
• The varying opinions may have contributed to investor uncertainty and increased volatility.
• Positive aspects of Illumina's business, like innovative technologies and market leadership, likely drove the bullish momentum.
• Market participants may have favored ILMN over HRMY due to factors such as growth potential, financial performance, or market positioning.

26.05.2025 - ILMN Stock was up 5.2%

• The positive market sentiment surrounding Illumina's acquisition of SomaLogic likely contributed to the bullish movement in the company's stock.
• Investors' optimism about the potential synergies and growth opportunities from the SomaLogic deal is driving increased buying interest in Illumina.
• The market's response reflects confidence in Illumina's long-term strategy and its position to benefit from the rising demand for advanced biomarker technologies in the biotechnology sector.

21.04.2025 - ILMN Stock was down 5.1%

• The bearish movement in ILMN stock today could be attributed to profit-taking by investors after a recent strong bullish run.
• Despite the positive news about the launch of the new DRAGEN v4.4 software, the market may have reacted negatively due to potential concerns about the actual impact on the company's financial performance.
• Significant increase in stake in Illumina by an influential investor might have initially boosted investor confidence, but the overall market sentiment may have been influenced by broader industry trends or macroeconomic factors impacting biotech stocks.
• It's possible that the market perceived ILMN's current valuation as stretched, leading to a correction despite the positive developments.

06.04.2025 - ILMN Stock was down 5.0%

• The bearish movement in ILMN today could be due to profit-taking by investors after a recent bullish run.
• Despite the positive expectations for earnings growth, market participants might have been disappointed by other underlying factors.
• It's possible that some investors were expecting even stronger performance, leading to a sell-off in the stock.
• Short-term market fluctuations can sometimes overshadow long-term growth prospects, causing abrupt price changes like the one observed today.

03.03.2025 - ILMN Stock was down 5.4%

• Keith Meister joining Illumina's board suggests the possibility of strategic shifts or growth endeavors within the company.
• Although Illumina has historically performed well, recent market reactions may reflect concerns or uncertainties related to the influence of the new board member on future decisions.
• Investors may be hesitant about potential alterations in Illumina's direction under Meister's guidance, prompting a short-term sell-off of the company's stock.

23.06.2025 - ILMN Stock was up 5.4%

• The positive movement in ILMN today could be linked to optimistic outlooks in the biotech field and potential growth possibilities.
• Speculations around Ark Invest purchasing shares of NVIDIA Corp amidst concerns regarding an AI initiative might have stirred confidence in the tech industry, indirectly influencing companies like Illumina.
• Detailed examination of Illumina's internal structure may have been somewhat overshadowed by broader market tendencies and favorable industry updates, contributing to the stock's upwards trend.
• Investors seem to view Illumina as a key player in the biotech sector, especially with ongoing advancements in genetic technologies and research.

22.03.2025 - ILMN Stock was up 5.1%

• Rep. Thomas Kean's recent notable acquisition of Illumina stock could be perceived as an endorsement of the company's future potential, which might positively impact investor confidence.
• The disclosure regarding insider purchasing actions likely influenced the upward momentum of Illumina's stock price today.
• Market participants could view this internal transaction as a favorable sign, potentially prompting heightened purchasing activity and contributing to the stock's upward trajectory.

09.04.2025 - ILMN Stock was down 5.0%

• Despite surpassing earnings and revenue estimates in Q1 of 2025, Illumina Inc. (ILMN) experienced a bearish movement.
• The market may have reacted negatively due to the year-over-year decrease in revenues, indicating potential concerns about future growth prospects.
• Investors might be cautious about the sustainability of Illumina's performance, leading to profit-taking and a downward pressure on the stock price.
• The slight misses in earnings and revenue estimates could have also contributed to the bearish sentiment, as investors may have been expecting even stronger results.

09.04.2025 - ILMN Stock was down 5.1%

• Despite surpassing Q1 earnings and revenue estimates, a downtrend was observed in the stock's movement.
• Potential high expectations from investors for even stronger results post-earnings might have triggered a sell-off.
• The market sentiment might have been influenced by general economic conditions or uncertainties about future growth prospects.
• Some investors may have opted for profit-taking, capitalizing on the recent upsurge in the stock.